Document is current
Any future updates will be listed below
-
Authors
Nielsen, Suzanne
Picco, Louisa
Murnion, Bridin
Winters, Bryony http://orcid.org/0000-0002-4973-0771
Matheson, Justin http://orcid.org/0000-0001-6248-3704
Graham, Myfanwy
Campbell, Gabrielle
Parvaresh, Laila
Khor, Kok-Eng
Betz-Stablein, Brigid
Farrell, Michael
Lintzeris, Nicholas
Le Foll, Bernard http://orcid.org/0000-0002-6406-4973
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1163961)
- License Information
-
More Information
Article History
Received: 14 December 2021
Revised: 10 February 2022
Accepted: 31 March 2022
First Online: 22 April 2022
Competing interests
: SN, NL and MF have been investigators on an untied education grant from Indivior for unrelated work. SN has received untied research grants from Seqirus to study prescription opioid overdose. BLF has received cannabis product from Aurora, Grants from Canopy and Alkermes, participated in an Advisory Board for Indivior (and few other industry related projects not related to the present work). NL has served on Advisory Boards for Chiesi Pharmaceuticals and Indivior, received research funding from Camarus AB. K-EK has previously received a speaker’s honorarium from Pfizer and Mundipharma, in addition to fees from an advisory board and an educational grant from Seqirus. MG is funded through the New South Wales Health Clinical Cannabis Medicines Program. All other authors have nothing to declare.
